Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01540227
Other study ID # CTN PT-011
Secondary ID
Status Terminated
Phase
First received February 16, 2012
Last updated April 4, 2018
Start date September 2011
Est. completion date November 10, 2016

Study information

Verified date April 2018
Source Ottawa Hospital Research Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Syphilis is a sexually transmitted infection that causes genital sores and rash, but in some circumstances may result in more severe and unexpected symptoms. These severe symptoms could include eye infections, meningitis (infection of the membranes covering the brain and spinal cord), and liver infection. If not properly treated, syphilis can also lead to heart problems and dementia (a decline in reasoning, memory and other mental abilities) years down the road. There has been an increase in the number of reported cases of syphilis in North America, Europe, and Australia over the past decade. The number of new syphilis infections in Canada has increased roughly 10-fold over the past 10 years.

Since 1943, the antibiotic penicillin has been used to treat syphilis; however, very little information has been gathered to determine the proper dose of penicillin or appropriate duration of treatment. Added to this, several studies have shown that the recommended dose of penicillin fails to cure syphilis in 20-30% of patients. Since the number of people infected with syphilis is increasing, and since syphilis has the potential to cause serious disease, the investigators need better information on how to treat syphilis effectively.

This study aims to determine whether the current dose of penicillin recommended to treat syphilis is sufficient to cure the infection. Specifically the investigators will try to determine whether the amount of penicillin in your blood 3 and 7 days after receiving treatment for syphilis is sufficient to cure the infection as demonstrated by a blood test 6 or 12 months from now. This study is a multi-centered trial based in Ottawa but with centers recruiting both in Montreal and Toronto. A total of 120 participants with syphilis will be recruited into this study. The treatment you will receive for syphilis in this study does not differ from that you would receive normally; the investigators are only observing the levels of penicillin in your blood and relating them with the outcome of treatment.


Recruitment information / eligibility

Status Terminated
Enrollment 25
Est. completion date November 10, 2016
Est. primary completion date November 10, 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

Participants must meet all of the following criteria to be considered eligible for entry into the study:

1. At least 18 years of age

2. Presenting with clinical signs of either primary or secondary syphilis; or with early latent syphilis and documented negative serology within the past 12 months.

3. Positive syphilis serology (reactive CMIA and TP-PA) with a defined RPR titer at the time of diagnosis and enrolment

4. Able to provide informed consent

5. Able to communicate in either English of French

6. Able to return for follow-up

Exclusion Criteria:

Participants are not eligible to participate in the study if any of the following conditions are met:

1. Diagnosis of late latent syphilis, tertiary syphilis, or syphilis of unknown duration

2. Allergy to penicillin

3. Diagnosis of neurosyphilis requiring treatment with intravenous penicillin

4. Treatment with doxycycline or ceftriaxone

5. Treatment with more than one intramuscular dose of benzathine penicillin G

6. Treatment with any antibiotics within the 6 weeks prior to enrolment

7. Pregnant or breastfeeding

8. Any immune modulating therapy

9. Patient is unable or unwilling to return for blood sampling at 3 and 7 days post treatment

Study Design


Intervention

Drug:
Regular Treatment for Syphilis
Drug: Benzathine Penicillin G (Bicillin) Dose: 2.4 million units Mode of Administration: intramuscular injection Duration of Treatment: one dose Health Canada approved indication: Yes

Locations

Country Name City State
Canada Ottawa Sexual Health Clinic/GayZone Ottawa Ontario
Canada The Ottawa Hospital Ottawa Ontario
Canada Toronto General Hospital Toronto Ontario

Sponsors (2)

Lead Sponsor Collaborator
Ottawa Hospital Research Institute CIHR Canadian HIV Trials Network

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Penicillin and Treatment Failure To determine if serum penicillin concentrations measured at days 3 and 7 post-treatment differ between those who achieve successful treatment of infectious syphilis versus those who experience treatment failure. 6 months post-treatment
Secondary HIV and Treatment Failure To determine if serum penicillin levels and treatment failures differ between HIV-positive and HIV-negative individuals. 6 months post-treatment
See also
  Status Clinical Trial Phase
Completed NCT03660488 - Cefixime for Alternative Syphilis Treatment Phase 2
Recruiting NCT05548426 - Linezolid for Syphilis Pilot Study Phase 2
Completed NCT02191527 - Evaluating the Effectiveness of Point-of-care Diagnostic Technologies in MCH Services in Mozambique N/A
Completed NCT01439503 - Safer Sex Program for Young African-American Men Phase 2
Completed NCT02257658 - Efficacy of Doxycycline Prophylaxis to Reduce Syphilis in High-Risk, HIV-Positive MSM N/A
Completed NCT02611765 - Syphilis Response to Higher Penicillin Dosage: The 2.4 Versus 7.2 Study Phase 4
Not yet recruiting NCT06428643 - A Seek, Test, and Treat Intervention to Reduce Chlamydia Trachomatis Disparities N/A
Completed NCT03709862 - Global Syphilis Sequencing
Completed NCT03637660 - Phase 4 Comparative Trial of Benzathine Penicillin G for Treatment of Early Syphilis in Subjects With or Without HIV Infection Phase 4
Active, not recruiting NCT03310424 - Transcriptomic and Next Generation Sequencing Approaches to Infection With Treponema Pallidum
Completed NCT00207506 - Lay Health Advisors for Sexually Transmitted Disease Prevention Phase 1/Phase 2
Completed NCT00213018 - Safety, Acceptability and Preliminary Effectiveness of Carraguard™ (PC-515) in Preventing HIV/STI Transmission Phase 2
Recruiting NCT06059443 - mLab App Plus: A Randomized Controlled Trial of a Mobile Health (mHealth) Intervention N/A
Completed NCT04480749 - Syphilis Self-testing to Expand Test Uptake Among Men Who Have Sex With Men (SST) Phase 4
Not yet recruiting NCT06058286 - MENJAGA: Continuous Quality Improvement for Antenatal HIV, Syphilis and Hepatitis B Testing in Indonesia N/A
Active, not recruiting NCT03980223 - Evaluation of Doxycycline Post-exposure Prophylaxis to Reduce Sexually Transmitted Infections in PrEP Users and HIV-infected Men Who Have Sex With Men Phase 4
Completed NCT01465607 - Implementation of an Efficacious Intervention for High Risk Women in Mexico N/A
Completed NCT00553111 - Video Tool to Promote Knowledge of Syphilis as Facilitator of HIV Transmission N/A
Active, not recruiting NCT06367621 - Retrospective Study of iStatis Syphilis Ab Test (POC)
Completed NCT02445846 - Dual Rapid HIV & Syphilis Tests in Zambia N/A